# Core G: Biomarker Core

> **NIH NIH P30** · UNIVERSITY OF CALIFORNIA-IRVINE · 2021 · $388,423

## Abstract

Core G: Biomarker Core
Project Summary/Abstract
Alzheimer's is a devastating, progressive disease that affects almost 6 million Americans and this number is
expected to rise to almost 14 million in the next three decades. The cost to us is immense, both on a personal
and on a financial level. Our National Plan to Address Alzheimer's Disease
(https://aspe.hhs.gov/report/national-plan-address-alzheimers-disease-2018-update) sets us on a path with
several concrete goals and strategies to cure and prevent AD. In particular, one goal we must achieve is the
early diagnosis of AD and its related disorders (AD/ADRD). If we can detect the disease early, even before
symptoms have started, efforts to slow or even halt the disease may be more effective and can lead to many
more years with a high quality of life. A key to this early detection is to develop biomarkers for the disease –
ways in which, through testing of blood or cerebrospinal fluid (CSF – collectively known as biofluids), brain
scans, or even cognitive testing – we can detect and efficiently monitor the disease and assess treatment. The
goal of the UCI Biomarker Core is to help researchers here and across the globe in both collecting and
analyzing data from existing measures and by developing novel measures for the purposes of identifying,
quantifying, and validating factors that influence the risk of AD across the lifespan.
The UCI ADRC Biomarker Core is set to provide state-of-the-art biomarker data and analyses and we will
apply these to both existing data in our ADRC and to new data we are collecting. We will collect not only
traditional biomarkers (blood, CSF for amyloid beta and tau, structural MRI scans, PET scans, etc.), but
develop novel biomarkers as well. Our researchers have several innovative potential MRI and cognitive /
behavioral biomarkers that the Core will be assisting with that have the potential to advance our overall goal of
effectively determining disease etiology, measuring progression, and assessing effectiveness of treatment. In
addition, we know that curing and preventing AD is a monumental challenge and that our final goal will only
happen through collaborative teams and over the course of academic generations. Part of our mission in the
UCI ADRC Biomarker core is therefore to share data and techniques with the research community. As big a
part, however, is to share our knowledge and expertise with the next generation of clinicians and researchers,
providing them with training and mentorship needed to rise to this challenge.

## Key facts

- **NIH application ID:** 10188387
- **Project number:** 5P30AG066519-02
- **Recipient organization:** UNIVERSITY OF CALIFORNIA-IRVINE
- **Principal Investigator:** Craig E Stark
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $388,423
- **Award type:** 5
- **Project period:** 2020-06-15 → 2025-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10188387

## Citation

> US National Institutes of Health, RePORTER application 10188387, Core G: Biomarker Core (5P30AG066519-02). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10188387. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*